AMES, Iowa, Oct. 20, 2016 (GLOBE NEWSWIRE) — NewLink Genetics Corporation (NASDAQ:NLNK) today announced that it will webcast its Analyst and Investor Day being held on Tuesday, October 25 at the Convene Meeting Center in New York City.
The Analyst and Investor Day will be webcast live and a link can be accessed at edge.media-server.com/m/p/8ewqspg8 or through the NewLink Genetics website, investors.linkp.com/events.cfm, starting at 12:45 pm ET. The presentation also will be posted to the Company’s website at www.newlinkgenetics.com following the event.
Institutional investors, portfolio managers or equity research analysts interested in attending can email achen@lavoiehealthscience.com to register. Please note that pre-registration is required to attend.
About NewLink Genetics Corporation
NewLink Genetics is a biopharmaceutical company at the forefront of discovering, developing and commercializing novel immuno-oncology product candidates to improve the lives of patients with cancer. NewLink Genetics’ portfolio includes biologic and small molecule immunotherapy product candidates intended to treat a wide range of oncology indications. NewLink Genetics’ product candidates are designed to harness multiple components of the immune system to combat cancer. For more information, please visit http://www.newlinkgenetics.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements of NewLink Genetics that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release are forward-looking statements, within the meaning of The Private Securities Litigation Reform Act of 1995. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “target,” “potential,” “will,” “could,” “should,” “seek” or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include any statements other than statements of historical fact. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that NewLink Genetics makes due to a number of important factors, including those risks discussed in “Risk Factors” and elsewhere in NewLink Genetics’ Annual Report on Form 10-K for the year ended December 31, 2015 and other reports filed with the U.S. Securities and Exchange Commission (SEC). The forward-looking statements in this press release represent NewLink’ Genetics’ views as of the date of this press release. NewLink Genetics anticipates that subsequent events and developments will cause its views to change. However, while it may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. You should, therefore, not rely on these forward-looking statements as representing NewLink Genetics’ views as of any date subsequent to the date of this press release.
Corporate Contact:
Jack Henneman
Chief Financial Officer
(515) 598-2561
Investor@linkp.com
Media and Investor Contacts:
Media
Ben Navon
LaVoieHealthScience
617-374-8800, ext. 108
bnavon@lavoiehealthscience.com
Investors
Beth Kurth
LaVoieHealthScience
617-374-8800, ext. 106
bkurth@lavoiehealthscience.com
